Bioteque Corporation (4107) Fair Value & Analysis
Healthcare · TW · Market cap 8.2B TWD
Fair value as of: Jun 24, 2026
Analysis
Bioteque Corporation (4107) currently trades at 116.50 TWD, while our model-based Fair Value estimate is 171.17 TWD — implying the stock looks roughly 46.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Bioteque Corporation manufactures and sells medical devices in Asia, South America, North America, and internationally. The company offers angiography catheter, balloon dilation catheter, guiding sheath, guide steel wire, y-type connector, multi-pipe joint, connecting pipe, y-type connector assembly, peripheral vascular guiding catheter, coronary balloon dilation catheter, central venous catheter, microcatheter assembly, injection tube sleeve assembly for radiographic catheters, micro-puncture guide assembly, closed suction catheter, oxygen masks and tubing, anesthesia mask, sprayer and spray mask, endotracheal tube, and tracheostomy tube. It also provides pig tail drainage tube assembly, pig tail drainage tube, percutaneous drainage catheter accessories, insertion of drainage catheter kit, puncture and insertion system, snap lock drainage catheter set, ureteral catheter, propulsion tube, ureteral balloon dilation catheter, subcutaneous pyelostomy with ureteral catheterization, kidn…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Bioteque Corporation (4107) undervalued?
What is the fair value of 4107?
What is the quality score of 4107?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.